ORIGINAL ARTICLE

EFFECTS OF PULSED ELECTROMAGNETIC FIELD THERAPY VERSUS EXTRA CORPOREAL SHOCK WAVE THERAPY ON PERIPHERAL CIRCULATION AND FUNCTIONAL BALANCE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY: RCT

1Ashraf Abdelaal Mohamed Abdelaal
2Amir Abdel-Raouf El-Fiky
3Mohamed Salah Eldien Mohamed Alayat

ABSTRACT

Background: Diabetic peripheral polyneuropathy (DPN) is an arousing problem that negatively affects body systems. Pulsed low frequency electromagnetic field (PLFEM) and Extracorporeal shock waves (ESW) are therapeutic modalities frequently used to treat varieties of pathological conditions. Objective of the study was to evaluate and compare effects of PLFEM and ESW on feet blood flow (maximum skin blood perfusion (SBP-max), minimum skin blood perfusion (SBP-min), and basal mean perfusion changes (BMCP)) (by Laser Doppler) and functional balance (by Berg balance scale "BBS") in patients with DPN.

Methods: Seventy patients with DPN were randomly assigned into PLFEM, ESW and control groups. PLFEM group received treatment twice weekly while ESW received treatment once weekly, for 12 weeks. Variables were evaluated pre-study (evaluation-1), post-study (evaluation-2) and 4-weeks post-treatment cessation (evaluation-3).

Results: At evaluation-2 and 3; SBP-max, SBP-min, BMCP and BBS showed significant increase in both PLFEM and ESW groups (P< 0.05) compared with non-significant changes in the control group (P> 0.5). At evaluation-2; SBP-max, SBP-min, BMCP and BBS mean values and percentages of change were [27.21±4.27(23.27 %), 10.51±2.32(50.004 %), 43.18±2.95(33.01 %)], [24.74±3.33(10.62 %), 8.69±2.58(21.15 %), 14.48±2.35(11.66 %), 40.13±2.35(23.12 %)] and [22.12(-0.05 %), 7.196(-0.1 %), 13.06±2.38(-0.09), 32.76(-0.1 %)] for LFPEM, ESW and control groups respectively (P<0.05).

Conclusion: While both PLFEM and ESW have significant long-term effects in improving lower extremity blood flow and functional balance in patients with DPN, but still PLFEM is more effective than ESW.

Keywords: Diabetic Neuropathy, Circulation, Balance, Electromagnetic, Shockwave.

Received 11th October 2016, revised 01st December 2016, accepted 06th December 2016

CORRESPONDING AUTHOR

*1Ashraf Abdelaal Mohamed Abdelaal
Lecturer, Department of Physical Therapy
Neuromuscular Disorders and its surgery, Faculty of Physical Therapy, Cairo University, Egypt.

2Amir Abdel-Raouf El-Fiky
Lecturer, Department of Physical Therapy for Cardiovascular/ Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Egypt.

3Mohamed Salah Eldien Mohamed Alayat
Assistant Professor, Department of Basic Science, Faculty of Physical Therapy, Cairo University, Egypt.

This article is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.
INTRODUCTION
Noninsulin-dependent diabetes (NIDD) is an arousing disorder that is commonly associated with variety of peripheral vascular consequences[1]. Diabetic neuropathy (DN) is rapidly growing problem that can appear within 10 years of the diabetes onset,[2] and appears earlier in NIDD than in type 1 diabetes mellitus (T1DM).[3] Microvascular dysfunction, blood flow restriction and neural oxygen tension deterioration[4] are main elements in DN pathogenesis. Lower limb disorders secondary to peripheral vascular and sensory disturbances commonly seen in patients with the NIDD are among primary reasons for hospitalization[5]. Diabetes-related Peripheral neuropathy (DPN) is an alarming complication of both T1DM and NIDD[6] that negatively affect the patient's ability to maintain normal mental and physical functions[7]. DPN is mainly discovered in patients with diabetes aged 40 years or more, [8] and is presented with varieties of manifestations[9] including impaired lower limbs sensory [10] and motor functions, [11] diminished proprioceptive sensitivity and balance, [12] improper walking patterns; all of which end in deteriorated physical performance and postural instability with subsequent increase in incidence of fall. [13] Increased health-related annual cost, [14] and mortality [15]. Diabetes-related neural damage is mainly due to microvascular injury of small blood vessels supplying nerves.[16]. It's a vicious circle; since microvascular disturbance is a major contributor to DPN, while DPN predisposes to further peripheral vascular insufficiency in patients with NIDD[17]. Vascular disorders in diabetic feet are common multifocal complications with accelerated progression, [18] that end in exaggerated motor disabilities [19]. Functional balance is an important prerequisite for proper task performance during static and dynamic situations that depends on complex interactions between the different sensory and motor systems components[20]. Functional balance defect is common in patients with DPN, either due to its direct effect on the neuromuscular system or altered postural strategies required to compensate for inadequate somatosensory inputs [21]. These disturbances hinder patients with PDN from safely performing daily living activities and predispose them for loss of balance during statics well as during complex dynamic tasks[22].

Treatment of NIDD should be directed towards correction of the underlying pathogenic mechanisms, treatment of associated symptoms, with targeting prevention and treatment of complications[23]. Current pharmacotherapy approaches primary objective is to reduce neuropathic pain[24]. Patients with DPN may find it difficult to start the treatment program with exercise training because of multiple comorbidities; so many physical modalities have been introduced to modulate pain, sensory loss, muscle weakness and many other symptoms in those patients[25]. Pulsed low frequency electromagnetic field (PLFEM) is an interesting therapeutic procedure [26], it achieved significant improvements when utilized in multiple peripheral vascular and musculoskeletal disorders treatment[27]. PLFEM can effectively enhance peripheral nerve function; modulate neuropathic pain and nerve impulse in patients with DPN[28]. Extracorporeal shock waves (ESWs) are acoustic waves with very high-pressure amplitude, fast pressure rise, very short pulse length and extremely short pulse rise time[29]. ESWs is non-invasive therapeutic modality with proven effectiveness in the treatment of various musculoskeletal disorders,[30] variety of dermatological disorders, burns, and diabetic foot wounds[31].

Variable physical modalities have been used to treat DPN, but many of them have not been compared with each other in effectiveness, [25] also long-term continued studies are warranted to assess the extent and long-term effectiveness of these therapeutic modalities[32]. Both PLFEM and Extracorporeal shock waves therapy (ESWT) have increased clinical utilization in various acute and chronic disorders. Up to date and recent researches; long-term effects of PLFEMT and ESWT on peripheral blood perfusion and functional balance were neither evaluated nor compared in patients with DPN. This study, therefore, aimed to evaluate and compare the efficacy of PLFEMT with that of ESWT in the treatment of DPN on a follow-up basis.

SUBJECTS AND METHODOLOGY

Participants
Seventy participants with NIDD and DPN were enrolled in this randomized controlled study. This number was chosen based on the power analysis procedure (1-β = 0.95, α = 0.05, effect size = 0.4) and patient's allocation into PLFEM group (n= 22), ESWT (n= 23) or Control Group (n= 25) was conducted via computer random generated numbers.

All participants (43 men and 27 women) matched the inclusion criteria, continue their regular medical and dietary regimens. Informed consents were obtained before the beginning of the study. There was no drop-out throughout the study course (Figure 1). The study adhered to the Helsinki Declaration of 1975, as revised in 2000 and was approved by the regional ethical committee.

The inclusion criteria were: Patients with NIDD of more than 10 years, age range 45 to 60 years, DPN more than 2 years duration, with fasting blood sugar values over 110 mg/dl, with glycated hemoglobin of more than 6.5 to less than 11 %, under oral route therapy, with well-controlled hyperglycemia over the last 3 months, with mild DPN (Valk polyneuropathy severity score between 2-9), with Snellen chart score value more than 16/20, sedentary life style, with documented balance disturbance (Berge balance scale “BBS” score less than 40).

Exclusion criteria were patients treated with insulin, with age of less than 45 or over 60, feet ulcerations, other sever complications that affect the study outcomes, patient participation and safety (including nephropathy, retinopathy, blood pressure abnormalities, serious musculoskeletal, vascular, or cardiac disorder), current smoking, patients who were under medications that affect balance or were familiar with the evaluation or treatment procedures. Ab-
sence of more than 2 treatment sessions was established as exclusion criteria.

Pre-study identical screening and evaluations were conducted for all participants. The principal assessed variables include blood flow parameters (max skin blood perfusion (SBP-max), minimal skin blood perfusion (SBP-min), and basal mean perfusion changes (BMCP) of the foot by Laser Doppler Flowmetry Periflux system and functional balance (FB) "through BBS". Evaluations were performed pre-study, post 12-weeks and 4-weeks after treatment cessation (follow-up). Data were handled according to standardized procedures. Variables assessment was done between 9-11 am. Fasting blood glucose (FBG) in mg/dl and HbA1c %, weight in kg, height in m all were initially evaluated at the beginning of the study.

**Evaluation of the skin blood flow**

Assessment of foot skin blood flow was conducted according to the previously prescribed procedure, [33] using laser Doppler flowmetry (Periflux system 5001) in which laser doppler probe 407 was connected to laser doppler perfusion measurement (LDPM) unite, connected to the computer. While assuming supine lying position for at least 5 min (in which patient was asked to remain as motionless as possible; skin blood flow parameters (SBP-max, SBP-min and BMCP of the lower extremity) were evaluated for each patient from the pulp of the great toe using (laser doppler flowmetry Periflux system 5001 (PF 5010 - LDPM unit), Primed, Sweden) with sampling frequency 32 Hz. The probe tip touched the tissue without over-pressure to prevent the false results. Local heat application for 3-5 minutes before blood flow evaluation was produced about by thermostatic probe. This combination procedure accurately clarifies the tissues viability and microcirculation compromise.

**Functional Balance evaluation (Berg Balance Scale)**

Functional balance was evaluated via the BBS according to well-established procedure [34]. BBS was used to evaluate FB, composed of 14 functional items, with 5-point scale (from 0 to 4 for each item in which 0 indicated failure of completion of the task, and 4 means success in carrying out the task independently). The higher score indicated a better functional balance.

**Treatments**

After comfortably seated on a “17 inches height” seat; patient in the PLFEM group was treated by resting each foot on a PLFEM plate for 30 min, two sessions/week, for 12 weeks.

Plates were connected to the PLFEM apparatus (Easy Qs device, ASA srl, Italy), with intensity of 50 % and frequency of 10 Hz.

The ESW was applied perpendicular to the skin via The Orthospec ESWT (Medispec LTD, Germantown, MD, USA). After proper cleaning of the treated area by alcohol while the patient assumed relaxed supine lying position; The ESW pattern of application was manipulated to cover the width of the region from above the malleoli till tip of the big toes then to the plantar aspect. ESW was applied on the dorsal, plantar and lateral aspects of the ankle and foot. ESW was applied in form of 1000 impulse/session, one week apart for 12 sessions, 0.32 mJ/mm²).

The control group received only their prescribed oral hypoglycemic medications with no share in any of neither PLFEM nor ESW.

**Statistical analysis**

Statistical analyses were performed using SPSS software (version 16.0). Data was expressed as mean ± SD. Descriptive statistical analysis was performed for all variables at the evaluation1, 2 and 3. Changes in mean values of skin blood flow parameters (SBP-max, SBP-min, and BMCP) of the lower extremity and FB (through BBS) within and between groups were analyzed. Repeated measures ANOVA with a Greenhouse-Geisser correction was used to determine if there were statistically significant differences in mean values of evaluated variables between the three evaluation points. Post hoc tests using the Bonferroni correction were done after that. The chi-square test of independence was used to test for equality of proportions between populations. The statistical significance was set to P<0.05.

**RESULTS**

Pre-study, there were non-significant differences in demographic characteristics between groups (p > 0.05), (Table I).
Pre-study results clarified that there were non-significant differences between the 3 groups neither in blood flow parameters (SBP-max, SBP-min, and BMCP) nor in FB scores. Data collected from all groups at the three evaluation points (pre-study “evaluation-1”, post-study “evaluation-2”, and 4 weeks post-treatment cessation “follow-up; evaluation-3”) were compared within and between groups (Tables 2, 3 & Figures 2, 3).

**Blood flow parameters (SBP-max, SBP-min, BMCP):**

Regarding SBP- max; There were significant increase in SBP-max mean values between the pre-study and post-study evaluations by (23.27 %) and (10.62 %) in the PLFEM and ESWT groups respectively (P<0.05), compared with non-significant decrease in SBP-max of the control group (-0.05-%) between the same evaluation points (P= 0.08). In spite of rebound of the SBP-max at (evaluation-3; follow-up) in all groups; there's still a significant increase in SBP-max mean values between the pre-study and the follow-up by (22.45 %) and (2.91 %) in the PLFEM and ESWT groups, respectively (P<0.05), compared with significant decrease in the control group (-0.14-%) between the same evaluation points (P=7.94^{-5}) (Table 2). Furthermore; There were statistically significant differences in mean values and mean percent changes of SBP-max between groups at the post-study and the follow-up; but in favor of the PLFEM group (p< 0.05) (Table 2, 3 & Figure 2).

Regarding SBP-min; There were significant increases in SBP-min mean values between the pre-study and post-study evaluations by (50.004 %) and (21.15 %) in the PLFEM and ESWT groups, respectively (P<0.05), compared with non-significant decrease in SBP-min of the control group by (-0.1-%) between the same evaluation points (P= 0.16). In spite of rebound of the SBP-min at the follow-up in all groups; there's still a significant increase in SBP-min mean values between the pre-study and the follow-up by (49 %) and (17.02 %) in the PLFEMT and ESWT groups, respectively (P<0.05), compared with significant decrease in the control group (-0.74-%) between the same evaluation points (P=7.94^{-5}) (Table 2). Furthermore; There were statistically significant differences in mean values and mean percent changes of SBP-min between groups at the post-study and the follow-up; but in favor of the PLFEM group (p< 0.05) (Table 3, 4 & Figure 2).

Regarding BMCP; There were significant increase in BMCP mean values between the pre-study and post-study evaluations by (24.45 %) and (11.66 %) in the PLFEM and ESWT groups, respectively (P<0.05), compared with non-significant decrease in BMCP of the control group by (-0.09-%) between the same evaluation points (P= 0.08). In spite of rebound of the BMCP at the follow-up in all groups; there's still a significant increase in BMCP mean values between the pre-study and the follow-up by (24.03 %) and (6.42 %) in the PLFEM and ESWT groups, respectively (P<0.05), compared with significant decrease in the control group by (-0.47-%) between the same evaluation points (P=2.65^{-5}) (Table II). There were statistically significant differences in mean values and mean percent changes of BMCP between groups at the post-study and the follow-up; but in favor of the PLFEM group (p< 0.05) (Table 3, 4 & Figure 2).

### Table 1: The demographic characteristics of participants in all groups (Mean ± SD)

| Variables            | PLFEMT group (N=22) | ESWT group (N=23) | Control group (N=25) | P value |
|----------------------|---------------------|-------------------|----------------------|---------|
| Age (year)           | 53.5 ± 5.41         | 53.83 ± 4.4       | 53.68 ± 5.6          | 0.98**  |
| Weight (kg)          | 80.05 ± 8.1         | 79.83 ± 6.65      | 81.04 ± 6.07         | 0.81**  |
| Height (m)           | 1.65 ± 0.05         | 1.64 ± 0.04       | 1.64 ± 0.34          | 0.7**   |
| BMI (Kg/m²)          | 29.58 ± 4.04        | 29.71 ± 2.58      | 30.14± 2.17          | 0.8 **  |
| FBG (mg/dl)          | 193.85 ± 9.42       | 195.41 ± 9.32     | 195.2 ± 15.39        | 0.89**  |
| HbA1c (%)            | 8.1 ± 0.74          | 8.1 ± 0.46        | 8.04 ± 0.6           | 0.92**  |
| Average T2DM duration (year) | 11.82 ± 1.18 | 11.8 ± 0.65 | 11.88 ± 0.74 | 0.95** |

PLFEMT: Pulsed Electromagnetic Field Therapy, ESWT: Extracorporeal shock waves therapy, FBG: fasting blood glucose, HbA1c: Glycated hemoglobin, T2DM: Type 2 diabetes mellitus, BMI: body mass index

* Significant (P< 0.05) ** Non-significant.
Table 2: Within group’s comparison of mean values of foot skin blood flow parameters and functional balance scores (F, P values).

|                     | PLFEMT group, (N=22) | ESWT group, (N=23) | Control group, (N= 25) |
|---------------------|----------------------|---------------------|------------------------|
|                     | Pre                  | Follow-up | Pre   | Post | Follow-up | Pre | Post | Follow-up |
| SBP-max Mean ± SD   | 22.32 ± 4.57         | 27.21 ± 4.27 | 27.04 ± 4.25 | 22.43 ± 3.35 | 24.74 ± 3.33 | 23.07 ± 3.45 | 23.47 ± 3.30 | 22.13 ± 3.05 | 22.12 ± 3.04 | 22.1 ± 3.04 |
| F, P values         | 569.86,1.06-16*     | 292.79,3.38-14**  | 3.27, 0.08**         |
|                     | 303.46, 1.09-13*     | 139.77, 7.33-13*  | 5.41, 0.012* |
| SBP-min Mean ± SD   | 7.3 ± 2.39           | 10.51 ± 2.32 | 10.46 ± 2.32 | 7.26 ± 2.32 | 8.69 ± 2.58 | 8.4 ± 2.52 | 7.2 ± 2.54 | 7.2 ± 2.53 | 7.15 ± 2.51 |
| F, P values         | 472.13, 7.1-16*      | 97.06, 1.58-9*   | 2.087, 0.16**          |
|                     | 231.90, 1.46-13*     | 145.9, 4.82-13*  | 14.64, 7.94-3* |
| BMCP Mean ± SD      | 13.12 ± 2.45         | 16.15± 2.22 | 16.09 ± 2.21 | 13.04 ± 2.43 | 14.48 ± 2.35 | 13.84 ± 2.41 | 13.07 ± 2.38 | 13.06 ± 2.38 | 13.01 ± 2.38 |
| F, P values         | 286.41,1.03-13*      | 180.85,4.33-12* | 3.27, 0.08**         |
|                     | 139.027, 1.85-12*    | 115.18, 4.79-12* | 17.25, 2.65-12* |
| BBS Mean ± SD       | 32.68 ± 3.76         | 43.18± 2.95 | 42.91 ± 2.78 | 32.87 ± 4.66 | 40.13 ± 3.52 | 38.61 ± 3.41 | 32.8 ± 4.42 | 32.76 ± 4.36 | 32.48 ± 4.29 |
| F, P values         | 856.06,1.67-10*      | 456.52,3.33-10* | 1, 0.33**          |
|                     | 459.1, 1.94-17*      | 346.69, 8.26-17* | 5.41, 0.012* |

**P**LEFMT: Pulsed Electromagnetic Field Therapy, **ESWT**: Extracorporeal shock wave therapy, **SBP-max**: maximum skin blood perfusion, **SBP-min**: minimum skin blood perfusion, **BMCP**: basal mean changes of perfusion, **BBS**: Berge Balance Scale, **F**: Significant (P< 0.05) **Non-significant.**

**Figure 2**: Between groups’ comparisons (Means ± SD) of maximum skin blood perfusion (SBP-max), minimum skin blood perfusion (SBP-min), and basal mean changes of perfusion (BMCP) for the 3 groups (Pulsed low frequency magnetic Field therapy (PLFEMT) group, Extracorporeal shock wave therapy (ESWT) group, and Control group) at the 3 evaluation points (Evaluation-1: Pre-study, Evaluation-2: Post study, and Evaluation-3: Follow-up; one month post-training cessation). **Significant: P< 0.05 **Non-significant.

**Figure 3**: Between groups’ comparisons (Means ± SD) of functional balance (Berg Balance Scale; BBS) for the 3 groups (Pulsed low frequency magnetic Field therapy (PLFEMT) group, Extracorporeal shock wave therapy (ESWT) group, and Control group) at the 3 evaluation points (Evaluation-1: Pre-study, Evaluation-2: Post study, and Evaluation-3: Follow-up; one month post-training cessation).
Table 3: Between group’s comparison of mean values of foot skin blood flow parameters and functional balance scores (F, P values).

| Variables     | Pre     | Post    | Follow-up | F, P values |
|---------------|---------|---------|-----------|-------------|
| SBP-max (PU)  | 12.03   | 12.14   | 462.3     | 1.51***     |
| SBP-min (PU)  | 10.46   | 10.79   | 383.62    | 4.57***     |
| BMCP (PU)     | 10.37   | 10.69   | 251.76    | 1.3***      |
| BBS           | 50.19   | 50.54   | 849.11    | 8.11***     |

PLFEMT: Pulsed Electromagnetic Field Therapy, ESWT: Extracorporeal shock wave therapy, SBP-max: maximum skin blood perfusion, SBP-min: minimum skin blood perfusion, BMCP: basal mean changes of perfusion, BBS: Berge Balance Scale.

*Significant; P< 0.05, **Significant, ***Non-significant, * Degree of freedom= 2, 67.

Table 4: Post-hoc multiple comparisons of mean values (between groups; P value).

|                  | PEMT & SWT groups (P value) | PEMT & Control groups (P value) | SWT & Control groups (P value) |
|------------------|-----------------------------|---------------------------------|-------------------------------|
| SBP-max (pre; eval-1) | 0.92**                      | 0.86**                          | 0.78**                        |
| SBP-max (post; eval-2) | 0.02*                       | 6.43**                          | 0.01*                         |
| SBP-max (follow-up; eval-3) | 4.35**                     | 1.32**                          | 0.35**                        |
| SBP_min (pre; eval-1) | 0.95**                      | 0.89**                          | 0.94**                        |
| SBP_min (post; eval-2) | 0.02*                       | 2.13**                          | 0.04*                         |
| SBP_min (follow-up; eval-3) | 0.01*                      | 1.80**                          | 0.08**                        |
| BMCP (pre; eval-1) | 0.91**                      | 0.94**                          | 0.96**                        |
| BMCP (post; eval-2) | 0.019*                      | 2.29**                          | 0.04*                         |
| BMCP (follow-up; eval-3) | 0.002*                    | 2.72**                          | 0.23**                        |
| BBS (pre; eval-1) | 0.884**                     | 0.97**                          | 0.96**                        |
| BBS (post; eval-2) | 0.01*                       | 2.55**                          | 2.17**                        |
| BBS (follow-up; eval-3) | 1.47**                     | 7.52**                          | 1.21**                        |

**Discussion**

The goal of this study was to explore and compare the effects of twelve-weeks PLFEM with that of the ESWT program on SBP-max, SBP-min, BMCP and BBS in patients with DPN. Results clarified the effectiveness of PLFEM and ESWT on peripheral blood perfusion and functional balance in patients with DPN. Results also revealed that PLFEM has more beneficial effects when compared with the ESWT in patients with DPN.

NIDD and DPN are associated with widespread and debilitating consequences, including increased risk and incidence of peripheral vascular disorders, [35] deteriorated somatosensory and motor functions, with progressive course of functional balance [36] and physical abilities [37] impairment. Treatment of DPN is a multi-disciplinary and long term approach that targets controlling the symptoms and improving the functional status [38]. PLFEM is a well-known therapeutic modality with documented therapeutic effectiveness in variable musculoskeletal and neurological disorders. PLFEM accelerates patient’s recovery, shorten the rehabilitation time, [39] and enhances the effectiveness of many medications prescribed for patients with DPN [40]. Peripheral vascular and neural deficits brought about by impaired microvascular perfusion and neural tissues ischemia are the leading causative factors for DPN in patients with NIDD [41]. Smith et al., 2004 reported that PLFEM can produce pronounced local arteriolar vasodilation in rat [42]. The observed vascular and functional improvements in PLFEM group came in accordance with the previously postulated and proved mechanisms in which PLFEM can empower the neural cell metabolism, and hence supports the neural function, [43] reverse the peripheral neuropathy damage through reducing endoneural hypoxia, improving microcirculation, arousing cell proliferation and modulating neural regeneration in patients with DPN [28]. Furthermore, PLFEMT repetitive application on the soles of feet in patients with DPN produces neural regeneration.
and reduces the accompanied neuropathic discomfort [44] through stimulation of opioid receptors and improving function of already deteriorated neurons [45]. PLFEMT can positively affect neuronal electrical activities through altering neuronal cell membrane potential and so ends in modulating nerve signals [33].

The main concept stands behind using PEMF in the treatment of DPN is the proved ability of the PLFEM to stimulate micro-vessel recruitment, [46] enhance perfusion, improve tissues and endoneurial microcirculation [47] and hence countering the peripheral vascular and neural ischemia. [48] PLFEM can also enhance functional recovery of the peripheral nerves [49]. Functional improvements in response to PLFEM in patients with DPN came in line with recently published studies that reported that PLFEM can be safely and effectively used in patients with DPN and balance deficits [32], [50]. Adding to that; PEMF can positively modulate neuromuscular activities[26], [27]. FB recovery in response to PLFEM can be further attributed to the fact that frequency-modulated electromagnetic neural stimulation is able to increase touch perception and motor conduction velocity in peripheral nerves [51]. Application of PLFEM has the ability to enhance the reflex excitability of functionally attenuated spinal cord motor neurons, increase neural conductivity and improve the function of 1a afferent nerve [52].

Extracorporeal shock waves are safe and effective physical modality used to enhance angiogenesis in the different pathologies, with the interval between sessions varied from 2 days to two weeks [53], [54]. The ESW is an adjunctive therapeutic modality that serves to prevent complications and improve lower limb circulation in patients with NIDD and DPN [41]. The favorable impact of ESW on tissue blood perfusion in the current study came in accordance with many previously published studies reported that ESWT can effectively enhance tissue blood perfusion and healing process in patients with full thickness burn. The ESWT - dependant increase in perfusion is associated with stimulation of vessel endothelial growth factor (VEGF), control of the inflammatory cascade, and enhanced tissue regeneration [55]. Tassery and Allaire, 2003 reported that ESW can stimulate release of endorphins and creating small tunnels through which new blood vessels can grow, and so enhancing the blood flow [56].

Beside the complete biological effects of ESWs action is not yet fully identified; ESWs produce favorable biological responses at the cellular level. ESWs enhance the release of cellular angiogenic growth factors and hence support revascularization and cell proliferation [57],[39]. ESWs can effectively stimulate biological regeneration, enhance blood supply and improve tissues’ metabolic processes [58], [29]. The increase in peripheral circulation in cases with NIDDM and DPN can be further explained on the basis that ESWT enhances endothelial nitric oxide (NO) synthase production and activity which is important for vasodilation, angiogenesis and neurotransmission [59]. ESWT increases basal NO production, rate of neuronal NO synthase and reduces the amount of exudates in lower extremities disorders [54]. Results of the current study were in line with that of Wang et al., 2003 who reported that the ESWT can effectively enhance the process of neovascularization at the bone-tendon injured site, [57] stimulate production and expression of angiogenesis-related markers, [31] protect against capillary endothelial damage, attenuate extracellular matrix proteolytic activity and hence maintain tissues vitality [60].

Although undertaken efforts to be unbiased; it was a hard task to mad the patients as well as therapists who were applying the PLFEMT or ESWs to be blind about the therapy type. To compensate for this point; randomization and evaluation procedures were performed blindly and delivered therapeutic program to each group was conducted by single therapist. Longer follow-up periods are warranted in the future studies to compensate for the relatively short-follow in this study.

CONCLUSIONS

According to the results of this study, both PLFEMT and ESWT are effective therapeutic modalities in increasing peripheral blood perfusion and functional balance in patients with PDN. PLFEMT is more effective than ESWs in increasing peripheral blood perfusion and functional balance in patients with PDN for an extended period of time.

List of abbreviations:

NIDD: Noninsulin-dependent diabetes, T1DM: Type 1 diabetes mellitus, DPN: Diabetic polyneuropathy, PLFEM: Pulsed low frequency electromagnetic field, ESWs: Extracorporeal shock waves, SBP-max: max skin blood perfusion, SBP-Min: minimal skin blood perfusion, BMCP: basal mean perfusion changes, FB: functional balance, FBG: Fasting blood glucose, LDPM: laser Doppler perfusion measurement, BBS: Berg Balance Scale, NO: nitric oxide.

REFERENCES

[1] Winnick JJ, Sherman WM, Habash DL, Stout MB, Failla ML, Belury MA, Schuster DP. Short-term Aerobic Exercise Training in Obese Humans with Type 2 Diabetes Mellitus Improves Whole-Body Insulin Sensitivity through Gains in Peripheral, Not Hepatic Insulin Sensitivity. J Clin Endocrinol Metab. 2008; 93 (3):771-778.
[2] Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care.2011;34:2220-4.
[3] Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al., Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010; 33(10):2285-93.
[4] Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diabet Med. 1995; 12:566-579.
[5] Urbani V, Stefanovska A, Bernjak A, Juvan K, Kocijani A. Skin Blood Flow in the Upper and Lower Extremities of Diabetic Patients with and without Autonomic
Neuropathy. J Vasc Res. 2004; 41:535-545.

[6] Fedele D, Comi G, Coscelli C, Cucinotta D, Feldman EL, Ghirlanda G, Greene DA, Negrin P, Santeusiano F: A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care. 1997; 20(5):836-843.

[7] Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005; 30:374-85.

[8] Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson J L. Harrison's Principles of Internal Medicine: Volume II. McGraw-Hill, Medical Publishing Division, 15th Edition; 2001; 258, 2123-2124.

[9] Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siiionen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:89-94.

[10] Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007;17(4):CD004572.

[11] Allet Ll, Armand S, de Bie RA, Pataky Z, Aminian K, Herrmann FR, de Bruin ED. Gait alterations of diabetic patients while walking on different surfaces. Gait Posture. 2009; 29:488-493.

[12] Turcot K, Allet L, Golay A, Hoffmeyer P, Armand S. Investigation of standing balance in diabetic patients with and without peripheral neuropathy using accelerometers. Clin Biomech. 2009; 24:716-721.

[13] Ites KI, Anderson EJ, Cahill ML, Kearney JA, Post EC, Gilchrist LS. Balance interventions for diabetic peripheral neuropathy: a systematic review. J Geriatr Phys Ther. 2011;34(3):109-16.

[14] Miranda-Massari1 JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control. Curr Clin Pharmacol. 2011; 6(4):260-273.

[15] Ekstrom W, Al-Ani AN, Saaf M, Cederholm T, Ponzier S, Hedstrom M. Health related quality of life, operation rate and function in patients with diabetes mellitus and hip fracture a 2 year follow-up study. Injury. 2013;44(6):769e75.

[16] American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2008; 31:12-54.

[17] Karvestedt L, Martensson E, Grill V, Elofsson S, von Wondt G, Hamsten A, Brismar K. Peripheral sensorimotor neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care. 2009;32:317-22.

[18] Dormandy J, Heeck L, Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg. 1999; 12: 138-41.

[19] Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A, Waterman C, Cavagnagh PR, Boulton AJ. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care. 2005, 28:2378-2383.

[20] Cimbiz A, Cakir O. Evaluation of balance and physical fitness in diabetic neuropathy patients. J Diabetes Complications. 2005; 19:160-4.

[21] Nardone A, Grasso M, Schiedepati M. Balance control in peripheral neuropathy: are patients equally unstable under static and dynamic conditions? Gait Posture. 2006; 23:364-73.

[22] Ghanavati T, Yazdi MJ, Goharpey S, Arastoo A-A. Functional balance in elderly with diabetic neuropathy. Diabetes Research and Clinical Practice. 2012, 96: 24-28.

[23] Casellini CM, Vinik AI. Clinical Manifestations and Current Treatment Options for Diabetic Neuropathies. Endocrine Practice. 2007; 13(5):550-566.

[24] Bril V1, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76: 1758-1765.

[25] Piber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med. 2010; 42(4) 289-95.

[26] Weintraub MI, Cole, SP. Pulsed magnetic field therapy in refractory neuropathic pain secondary to peripheral neuropathy: electrodiagnostic parameters-pilot study. Neurehabil Neural Repair. 2004; 18:42-6.

[27] Musaev AV, Guseinova SG, Imamverdieva SS. The use of pulsed electromagnetic fields with complex modulation in the treatment of patients with diabetic polyneuropathy. Neurosci Behav Physiol. 2003; 33: 745-52.

[28] Graak V, Chaudhary S, Ball BS, Sandhu JS. Evaluation of the efficacy of pulsed electromagnetic field in the management of patients with diabetic polyneuropathy. Int J DiabDevCtries. 2009; 24-28.

[29] Jankovic D. Case study: shock waves treatment of diabetic gangrene. Int Wound J. 2011; 8:206-209.

[30] Thomson CE, Crawford F, Murray GD. The effectiveness of extracorporeal shock wave therapy for plantar heel pain: A systematic review and meta-analysis. BMC Musculoskelet Disord. 2005;6:19.

[31] Wang CJ, Kuo YR, Wu RW, Liu RT, Hsu CS, Wang FS. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. J Surg Res. 2009; 152:96-103.

[32] Abdelaal AA, Abdelgalil AA. Effects of Pulsed Electromagnetic Therapy on Functional Capacity and Fall Risk in Patients with Diabetic Polyneuropathy:
Randomized Controlled Trial. International Journal of Therapies and Rehabilitation Research. 2015; 4(4): 95-103.

[33] Mabrouk MI, Badr NM, Taha MM, El Shiwi AF, Abdelaal AA, Ali SM, Abd El Hamed AM. Effect of extracorporeal shock wave therapy on skin blood perfusion in patients with diabetic foot: Randomized controlled trial. International Journal of Advanced Research. 2015; 3(3): 689-696.

[34] Berg KO, Wood-Dauphinee SL, Williams JI, Maki BE. Measuring balance in the elderly: validation of an instrument. Can J Public Health. 1992; 83(Suppl. 2):S7–11.

[35] American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.2003; 26:S5-S20.

[36] BonnetC, CarelloC, Turvey MT. Diabetes and postural stability: Review and hypotheses. J Mot Behav. 2009; 41(2): 172-90.

[37] Resnick HE1, Vinik AI, Schwartz AV, Leveille SG, Brancati FL, Balfour J, Guralnik JM. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: theWomen's Health and Aging Study. Diabetes Care. 2000; 23(11):1642-1647.

[38] Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2011; 4: 289-305.

[39] Quittan M. Clinical effectiveness of magnetic field therapy; a review of the literature. Acta Med Aturaca. 2000; 27 (3):61-68.

[40] Whissell PD,Persinger MA. Emerging synergisms between drugs and physiologically-patterned weak magnetic fields: implications for neuropharmacology and the human population in the twenty-first century. CurrNeuropharmacol, 2007; 5: 278-288.

[41] Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care.2005; 28: 956-62.

[42] Smith TL, Wong-Gibbons D, Maultsby J. Microcirculatory effects of PEMF. J Ortho Res. 2004; 22:80-4.

[43] Bassett LA. Beneficial effects of electromagnetic fields.J Cell Biochem.1993; 51: 387-93.

[44] Weintraub MI, Herrmann DN, Smith AG, Backonja ME, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: A randomized controlled trial. Arch Phys Med Rehabil. 2009; 90(7):1102-1109.

[45] Thomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes. 1997; 46 (Suppl 2):S54-7.

[46] Mayrovitz HN, Larsen PB. A preliminary study to evaluate the effect of pulsed radio frequency field treatment on lower extremity pericell skin microcirculation of diabetic patients .Wounds. 1995; 7:90-93

[47] Yen-Patton GP, Patton WF, Beer DM, Jacobson BS. Endothelial cell response to pulsed electromagnetic fields; stimulation of growth rate and angiogenesis in vitro. J. Cell Physiol. 1988; 134:37-64.

[48] Gilcreast DM, Stottsma NA, Froelicher ES, Baker LL, Moss KM. Effect of electrical stimulation on foot skin perfusion in persons with or at risk for diabetic foot ulcers. Wound Repair Regen.1998; 6:434-441.

[49] Kim SI, Im WS, Kang L, Lee ST, Chu K, Kim BI. The application of magnets directs the orientation of neurite outgrowth in cultured human neuronal cells. J Neurosci Methods.2008; 174: 91–96.

[50] Filimban WA, El-Fiky AA-R, Helal OF, Abdelaal AA. Effect of Magnetic Therapy on Balance Deficits in Patients with Diabetic Polyneuropathy: Randomized Controlled Trial. Jokull J. 2015; 65(3):187-196.

[51] Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni MC, Galimberti G, Scionti L. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia.2005; 48(5): 817-82.

[52] Abu El-Asrar AM, Al-Rubeaan KA, Al-Amro SA, Kangave D, Moharram OA. Risk factors for diabetic retinopathy among Saudi diabetics.International Ophthalmology. 1999; 22 (3): 155-161.

[53] Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, Matsumoto Y, Kajihara N, Eto M, Matsuda T, Yasui H, Takeshita A, Sunagawa K. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation.2004; 110(19):3055-61.

[54] Saggini R, Figus A, Troccola A, Cocco V, Saggini A, Scuderii N. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. Ultrasound Med Biol. 2008, 34(8):1261-71.

[55] Arno A, Garcia O, Hernan I, Sancho J, Acosta A, Barret JP. Extra corporeal shock waves a new non-surgical method to treat severe burns. Burn. 2010; 80(25): 119-129.

[56] Tassery F,Allaire T. Radial shock wave therapy for the treatment of lower limbs.FIBA Assist Magazine. 2003; 3: 57-58.

[57] Wang CJ, Yang KD, Wang FS, Huang CC, Yang LJ. Shock wave induces neovascularization at the tendon–bone junction. A study in rabbits.J Orthop Res. 2003;21:984-9.

[58] Gutersohn A, Caspari G, Erbel R. Autoangiogenesis induced by cardiac shock wave therapy (CSWT) increases perfusion and exercise tolerance in end-stage CAD patients with refractory angina. Circ J. 2005;69(Suppl I):379.

[59] Ciampa AR, Prati AC, Amelio E, Cavaleri E, Persichini T, Colasanti M, Musci G, Marlinghaus E, Suruki H and Mariotto S. Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS letters.2005; 579 (19): 6839-6845.

[60] Davis TA, Stojadinovic A, Amare K, Anam M, Naik S, Peoples EE, Tadaki D and Elster EA. Extra cor-
poreal shockwave therapy suppresses the acute early pro-inflammatory immune response to a severe cutaneous burn injury. Int. Wound Journal. 2009; 6:11-21

**Citation**
Ashraf A.A.M., El-Fiky R.A.A., & Alayat M.S. (2016). EFFECTS OF PULSED ELECTROMAGNETIC FIELD THERAPY VERSUS EXTRACORPOREAL SHOCK WAVE THERAPY ON PERIPHERAL CIRCULATION AND FUNCTIONAL BALANCE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY: RCT. *International Journal of Physiotherapy*, 3(6), 711-720.